Low risk of hepatitis B virus reactivation in HBsAg-negative/anti-HBc-positive carriers receiving rituximab for rheumatoid arthritis: A retrospective multicenter Italian study

Journal of Rheumatology

Volumn 43, Issue 5, 2016, Pages 869-874

  Varisco, Valentina ^a   Viganò, Mauro ^b   Batticciotto, Alberto ^a   Lampertico, Pietro ^b   Marchesoni, Antonio ^c   Gibertini, Patrizia ^c   Pellerito, Raffaele ^d   Rovera, Guido ^d   Caporali, Roberto ^e   Todoerti, Monica ^e   Covelli, Michele ^f   Notarnicola, Antonella ^f   Atzeni, Fabiola ^a   Sarzi Puttini, Piercarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Rheumatology Day Hospital   (Italy)

^d MAURIZIANO HOSPITAL   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f University Rheumatology Department   (Italy)

Author keywords

HBsAg; HBV DNA; Hepatitis B virus reactivation; Rheumatoid arthritis; Rituximab

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; VIRUS DNA; VIRUS ENVELOPE PROTEIN; ANTIRHEUMATIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE CARRIER; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; ITALY; LABORATORY TEST; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTPATIENT; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEX RATIO; VERY ELDERLY; VIRUS REACTIVATION; COMBINATION DRUG THERAPY; DRUG EFFECTS; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR; VIRUS ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; RITUXIMAB; VIRUS ACTIVATION;

EID: 84969269080     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.151105     Document Type: Article

References (30)

1. Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76.
2. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007;3:86-95.
3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
4. Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009;9:10-25.
5. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010;47:187-98.
6. Viganò M, Mangia G, Lampertico P. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. Expert Opin Biol Ther 2014;14:1019-31.
7. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-7.
8. Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006;130:823-37.
9. Rituxan (rituximab) package leaflet. [Internet. Accessed January 18, 2016.] Available from: www.gene.com/download/pdf/rituxan-prescribing.pdf
10. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-11.
11. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013;31:2765-72.
12. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al; Taiwan Cooperative Oncology Group. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2014;59:2092-100.
13. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85.
14. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
15. Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010;28:3199-202.
16. Mitroulis I, Hatzara C, Kandili A, Hadziyannis E, Vassilopoulos D. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2013;72:308-10.
17. Barone M, Notarnicola A, Lopalco G, Viggiani MT, Sebastiani F, Covelli M, et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology 2015;62:40-6.
18. Gigi E, Georgiou T, Mougiou D, Boura P, Raptopoulou-Gigi M. Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab. Hippokratia 2013;17:91-3.
19. Salman-Monte TC, Lisbona MP, García-Retortillo M, Maymó J. Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab. Reumatol Clin 2014;10:196-7.
20. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
21. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
22. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003;23:39-46.
23. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005;34 Suppl 1:S1-3.
24. Kim HY, Kim W. Chemotherapy-related reactivation of hepatitis B infection: updates in 2013. World J Gastroenterol 2014;20:14581-8.
25. Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014;11:209-19.
26. Buti M, Morillas R, Manzano ML, García-Retortillo M, Gutiérrez ML, Martín L, et al. Tenofovir for the prophylaxis of HBV reactivation in anti-HBc-positive patients with hematologic malignancies treated with rituximab: preliminary results of a randomized study (PREBLIN Study). J Hepatol 2014;60 Suppl:S421-2.
27. Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer 2013;49:3486-96.
28. Ji D, Cao J, Hong X, Li J, Wang J, Chen F, et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol 2010;85:243-50.
29. Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 2011;90:1219-23.
30. Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 2012;91:1007-12.